POINT Biopharma Global Inc. financial data

Industry
Pharmaceutical Preparations
Location
4850 West 78 Th Street, Indianapolis, IN
Fiscal year end
December 31
Former names
Therapeutics Acquisition Corp. (to 6/30/2021)
Latest financial report
10-Q - Q3 2023 - Nov 13, 2023

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 738 % -57%
Return On Equity 21.1 %
Return On Assets 18.3 %
Operating Margin 44.2 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 107M shares +0.88%
Common Stock, Shares, Outstanding 106M shares +1.64%
Entity Public Float 504M USD -23%
Common Stock, Value, Issued 10.6K USD +1.64%
Weighted Average Number of Shares Outstanding, Basic 106M shares +14.5%
Weighted Average Number of Shares Outstanding, Diluted 106M shares +14.5%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 244M USD
Research and Development Expense 113M USD +77.6%
General and Administrative Expense 22.9M USD +40.4%
Operating Income (Loss) 108M USD -20.3%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 127M USD -0.3%
Income Tax Expense (Benefit) 30.6M USD +5862%
Net Income (Loss) Attributable to Parent 96.6M USD -3.17%
Earnings Per Share, Basic 1.12 USD/shares +11.5%
Earnings Per Share, Diluted 1.1 USD/shares +11.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 21.6M USD -82.8%
Other Assets, Current 493K USD +123%
Assets, Current 353M USD +19.2%
Property, Plant and Equipment, Net 34.8M USD +70.7%
Operating Lease, Right-of-Use Asset 5.51M USD
Assets 478M USD +46.7%
Accounts Payable, Current 8.89M USD +178%
Accrued Liabilities, Current 14.5M USD +11.4%
Contract with Customer, Liability, Current 12.6M USD
Liabilities, Current 38.7M USD +133%
Contract with Customer, Liability, Noncurrent 3.72M USD
Accrued Income Taxes, Noncurrent 2.39M USD
Deferred Income Tax Liabilities, Net 0 USD -100%
Operating Lease, Liability, Noncurrent 4.64M USD
Liabilities 53.5M USD +222%
Accumulated Other Comprehensive Income (Loss), Net of Tax -1.43M USD -135%
Retained Earnings (Accumulated Deficit) -27.7M USD +77.7%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 424M USD +37.2%
Liabilities and Equity 478M USD +46.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -22.4M USD -113%
Net Cash Provided by (Used in) Financing Activities 146K USD +15385%
Net Cash Provided by (Used in) Investing Activities -153M USD -16165%
Common Stock, Shares Authorized 430M shares 0%
Common Stock, Shares, Issued 106M shares +1.64%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -175M USD -1434%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 21.6M USD -82.8%
Interest Paid, Excluding Capitalized Interest, Operating Activities 0 USD -100%
Deferred Tax Assets, Valuation Allowance 21.8M USD +36.1%
Deferred Tax Assets, Gross 23.1M USD +44%
Operating Lease, Liability 5.58M USD
Depreciation 538K USD +140%
Payments to Acquire Property, Plant, and Equipment 3.52M USD +275%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent 95.7M USD -3.53%
Lessee, Operating Lease, Liability, to be Paid 7.97M USD
Property, Plant and Equipment, Gross 36.7M USD +78.3%
Operating Lease, Liability, Current 940K USD
Lessee, Operating Lease, Liability, to be Paid, Year Two 798K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 690K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 2.39M USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 746K USD
Deferred Tax Assets, Operating Loss Carryforwards 425K USD -96.7%
Preferred Stock, Shares Issued 0 shares
Unrecognized Tax Benefits 1.5M USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 769K USD
Additional Paid in Capital 453M USD +4.47%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 1.28M USD +28955%